Lumiracoxib: Selective COX-2 Inhibitor for Research Applications

Executive Summary: Lumiracoxib is a potent, selective cyclooxygenase-2 (COX-2) inhibitor (IC50: 0.14 μM, Ki: 0.06 μM) with a >500-fold selectivity over COX-1, widely used in research to dissect inflammatory and angiogenic pathways (source: product_spec). It is chemically defined as 2-[2-(2-chloro-6-fluoroanilino)-5-methylphenyl]acetic acid, with a molecular weight of 293.72, and is soluble in DMSO (≥29.4 mg/mL) and ethanol (≥27.15 mg/mL, ultrasonic assistance); it is insoluble in water (source: product_spec). In tissue injury models, early COX-2 inhibition exacerbates ischemia but later promotes angiogenesis via VEGF and MMP upregulation (source: DOI). APExBIO supplies Lumiracoxib (SKU: B1458) at research grade, validated by HPLC, NMR, and MSDS. The compound is best stored at -20°C; solutions should not be stored long-term (source: product_spec).

Biological Rationale

The cyclooxygenase-2 (COX-2) pathway is central to the regulation of inflammation, pain, and tissue regeneration. COX-2 catalyzes the conversion of arachidonic acid to prostaglandins (PGs), which modulate vascular tone, immune cell recruitment, and extracellular matrix remodeling (source: DOI). In skeletal muscle injury models, PGs derived from COX-2 promote angiogenesis and recovery, but excessive or untimely activity can worsen ischemic injury (source: DOI). Selective inhibition of COX-2 allows researchers to distinguish its effects from those of the constitutive COX-1 isoform, which is vital for homeostatic prostaglandin functions.

Mechanism of Action of Lumiracoxib

Lumiracoxib acts as a highly selective inhibitor of COX-2, binding to its active site with an IC50 of 0.14 μM and a Ki of 0.06 μM (source: product_spec). The compound exhibits over 500-fold selectivity for COX-2 versus COX-1, minimizing interference with COX-1-mediated physiological processes such as gastric protection and platelet aggregation (source: internal_article). This selectivity enables precise modulation of the inflammatory cascade and prostaglandin synthesis in experimental models. When administered in muscle injury models, lumiracoxib suppresses COX-2-driven prostaglandin E2 (PGE2) and PGD2 production, impacting angiogenic and regenerative signaling (source: DOI).

Evidence & Benchmarks

• Lumiracoxib demonstrates an IC50 of 0.14 μM for COX-2 inhibition and a selectivity ratio of 515 over COX-1 (source: product_spec).
• In Bothrops asper venom-induced muscle injury models, early administration of lumiracoxib aggravates limb ischemia but subsequently enhances VEGF and MMP-mediated angiogenesis at later stages (source: DOI).
• COX-2 inhibition with lumiracoxib leads to decreased PGE2 and PGD2 production in early stages of tissue injury, affecting vascular regeneration (source: DOI).
• The compound is insoluble in water but dissolves at ≥29.4 mg/mL in DMSO and ≥27.15 mg/mL in ethanol with ultrasonic assistance (source: product_spec).
• APExBIO provides research-grade lumiracoxib with ~98% purity and robust QC documentation (source: product_spec).

For more on the temporal effects of COX-2 inhibition in muscle injury, see COX-2 Pathway Modulation in Muscle Ischemia Post-Venom Injury, which this article updates by providing focused guidance on protocol design and compound handling.

Applications, Limits & Misconceptions

Lumiracoxib is primarily used in preclinical and translational research to elucidate the role of selective COX-2 inhibition in models of inflammation, vascular injury, and muscle regeneration (source: DOI). Its high selectivity is crucial for experiments requiring minimal COX-1 interference. The compound has been pivotal in studies dissecting prostaglandin-dependent angiogenesis and in designing time-sensitive assays for tissue recovery. However, its pharmacokinetic properties and regulatory status limit its use to research applications only.

Common Pitfalls or Misconceptions

• Not suitable for clinical use: Lumiracoxib is for research only, not approved for therapeutic applications (source: product_spec).
• Water insolubility: Attempting to dissolve lumiracoxib in aqueous buffers leads to precipitation; DMSO or ethanol is required (source: product_spec).
• Timing of administration: Early COX-2 inhibition can worsen acute ischemia in muscle injury models; careful protocol timing is essential (source: DOI).
• Long-term storage of solutions: Lumiracoxib solutions are not stable for extended periods; prepare fresh aliquots as needed (source: product_spec).
• COX-1 compensation: In some models, COX-1-derived prostaglandins may partially compensate for COX-2 inhibition, complicating data interpretation (source: DOI).

For a strategic, protocol-focused discussion of these timing effects, see Navigating COX-2 Modulation in Muscle Injury: Strategic Use of Lumiracoxib, which this article extends by detailing real-world assay parameters and compound handling.

Workflow Integration & Parameters

Protocol Parameters

• COX-2 selective inhibition assay | IC50: 0.14 μM (human recombinant enzyme, 37°C) | In vitro enzymatic studies | Provides high sensitivity for detection of anti-inflammatory effects | product_spec
• COX-1 cross-reactivity assay | Selectivity ratio: 515-fold over COX-1 | Comparative COX-1/COX-2 assays | Ensures minimal off-target effects on homeostatic prostanoids | product_spec
• Solubility testing | ≥29.4 mg/mL in DMSO, ≥27.15 mg/mL in ethanol (ultrasonic) | Compound preparation for cell or tissue assays | Enables preparation of high concentration stock solutions | product_spec
• Storage conditions | Store at -20°C, avoid long-term storage of solutions | Compound handling for reproducibility | Preserves compound stability and prevents degradation | product_spec
• Muscle injury model timing | Early (0–24 h) vs. late (7–21 d) post-injury dosing | In vivo muscle regeneration assays | Early inhibition worsens ischemia, later promotes angiogenesis | DOI

For further insights on the dual timing effects of COX-2 pathway modulation, see Strategic COX-2 Inhibition: Lumiracoxib in Muscle Regeneration, which this article clarifies by summarizing compound-specific solubility and QC parameters.

Conclusion & Outlook

Lumiracoxib, as provided by APExBIO, is a robust, highly selective COX-2 inhibitor that enables precise modulation of the cyclooxygenase-2 pathway in both in vitro and in vivo research. Key evidence demonstrates its utility in dissecting time-dependent effects of COX-2 inhibition on ischemia and angiogenesis in muscle regeneration models (source: DOI). Protocol optimization—including solubility handling and timing of administration—is critical to experimental success. Future studies are expected to refine our understanding of COX-2/COX-1 compensation and to expand the toolkit for modeling inflammation and vascular repair. For additional technical details or to purchase, visit the Lumiracoxib product page.